Form 13-F position report

ALAUNOS THERAPEUTICS, INC. COM

Reported by GEODE CAPITAL MANAGEMENT LLC

TCRT CUSIP 98973P101 Manager CIK 0001214717

Reported 2,074,817 shares, down 1,451,623 (41.2%) from the prior quarter.

Reported value 11.8%; share count -41.2% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 2,074,817 Quarter-end amount reported
Reported value $2,572,000 Fair value at quarter end
Consecutive quarters held 37 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 3902000
2022-03-31 2300000
2022-06-30 2572000
2022-09-30 3571000
2022-12-31 1359000
2023-03-31 1346083
2023-06-30 1149757
2023-09-30 285217
2023-12-31 159558
2024-03-31 0
2024-03-31 272318
2024-06-30 114373
2024-09-30 53746
2024-09-30 0
2024-12-31 28918
2025-03-31 22640
2025-06-30 77355
2025-09-30 38539
2025-12-31 63758
2026-03-31 64532
2026-06-30 43753
2026-09-30 16964

Quarterly position history

How this manager's reported quarter-end position changed over time.

22 quarters
Quarterly reported position history for ALAUNOS THERAPEUTICS, INC. COM held by GEODE CAPITAL MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 19,291 -65 (-0.3%) < 0.01% $16,964 2026-11-06
Q2 2026 Reduced 19,356 -3,204 (-14.2%) < 0.01% $43,753 2026-08-12
Q1 2026 Added 22,560 +2,824 (14.3%) < 0.01% $64,532 2026-05-15
Q4 2025 Added 19,736 +3,945 (25.0%) < 0.01% $63,758 2026-02-09
Q3 2025 Reduced 15,791 -155 (-1.0%) < 0.01% $38,539 2025-11-12
Q2 2025 Added 15,946 +336 (2.2%) < 0.01% $77,355 2025-08-08
Q1 2025 Added 15,610 +394 (2.6%) < 0.01% $22,640 2025-05-13
Q4 2024 Reduced 15,216 -1,117 (-6.8%) < 0.01% $28,918 2025-02-12
Q3 2024 Reduced 0 -163,588 (-100.0%) 0 $0 2024-11-12
Q3 2024 New 16,333 +16,333 (0.0%) < 0.01% $53,746 2024-11-12
Q2 2024 Added 163,588 +13,171 (8.8%) < 0.01% $114,373 2024-08-09
Q1 2024 New 150,417 +150,417 (0.0%) < 0.01% $272,318 2024-05-13
Q1 2024 Reduced 0 -2,256,351 (-100.0%) 0 $0 2024-05-13
Q4 2023 Added 2,256,351 +92,878 (4.3%) < 0.01% $159,558 2024-02-13
Q3 2023 Reduced 2,163,473 -90,953 (-4.0%) < 0.01% $285,217 2023-11-13
Q2 2023 Added 2,254,426 +117,786 (5.5%) < 0.01% $1,149,757 2023-08-11
Q1 2023 Added 2,136,640 +42,302 (2.0%) < 0.01% $1,346,083 2023-05-15
Q4 2022 Added 2,094,338 +17,840 (0.9%) < 0.01% $1,359,000 2023-02-13
Q3 2022 Added 2,076,498 +1,681 (0.1%) < 0.01% $3,571,000 2022-11-14
Q2 2022 Reduced 2,074,817 -1,451,623 (-41.2%) < 0.01% $2,572,000 2022-08-12
Q1 2022 Reduced 3,526,440 -53,987 (-1.5%) < 0.01% $2,300,000 2022-05-13
Q4 2021 Added 3,580,427 +240,885 (7.2%) < 0.01% $3,902,000 2022-02-11
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

161 managers reported ALAUNOS THERAPEUTICS, INC. COM for Q2 2022.

Managers reporting ALAUNOS THERAPEUTICS, INC. COM in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
MSD Partners L P Unchanged 15,151,516 0 1.16% $18,788,000 37 qtrs
DISCOVERY CAPITAL MANAGEMENT LLC CT Added 14,125,079 +111,986 2.26% $17,515,000 14 qtrs
VANGUARD GROUP INC Reduced 9,295,855 -1,482,815 < 0.01% $11,527,000 37 qtrs
BlackRock Inc Reduced 5,237,799 -11,466,134 < 0.01% $6,495,000 36 qtrs
Laurion Capital Management LP New 4,289,193 +4,289,193 0.08% $5,319,000 1 qtr
JPMorgan Chase & Co Added 4,218,482 +938,994 < 0.01% $5,231,000 19 qtrs
MILLENNIUM MANAGEMENT LLC Added 2,169,705 +1,627,693 < 0.01% $2,690,000 13 qtrs
GEODE CAPITAL MANAGEMENT LLC This report Reduced 2,074,817 -1,451,623 < 0.01% $2,572,000 37 qtrs
TWO SIGMA ADVISERS LP Reduced 1,950,892 -785,900 < 0.01% $2,419,000 10 qtrs
SUSQUEHANNA INTERNATIONAL GROUP LLP Added 1,149,702 +786,202 < 0.01% $1,426,000 37 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 12, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
2,074,817
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.